Recently, Shenzhen Huada Gene Research Institute used the “non-invasive prenatal genetic testing†technology to collect some genomic samples from more than 140,000 Chinese pregnant women. The sequencing objects involved in this study account for about one ten-thousandth of China's total population, including 36 other ethnic minorities except the Han nationality. This is by far the largest Chinese genome sequencing and analysis to reveal genes. Linking to fertility and understanding the genetic structure of the Chinese population can be very helpful. The results of this study were published in the American journal Cell, and the genetic testing technology was reintroduced into the public eye. As an important branch of life science engineering, gene sequencing technology has become the focus of clinical diagnosis and medical research since its birth. The most widely used gene detection technology in the medical field is consumer-grade genetic testing. Before birth, gene sequencing can help test-tube babies, helping parents with genetic defects themselves to breed healthy next generations; during pregnancy, testing for fetal polyploids by non-invasive prenatal testing; It is not only the genetic gene for detecting somatic cells, but also the cause of the pathogens... Jobs spent about $100,000 on genetic testing after suffering from pancreatic cancer. Hollywood star Angelina Jolie also detected BRCA1 gene defects in 2013 through genetic testing, which has improved disease prevention and to some extent. In the early days of the rise, genetic testing seems to be out of reach for the general public because of the high price. However, in recent years, as the cost of genetic testing has decreased, as a bridge between life and clinical, medical and health care, consumer-grade genetic testing has become increasingly popular. The decline in cost has led to the rapid rise of the genetic testing market, and many companies have sprung up, making the genetic testing industry a major trend in recent years. Tumor immunity is the focus of future development of genetic testing In recent years, with the development of technology, more gene companies have begun to transfer genetic testing from the consumer line business and auxiliary appreciation to the oncology business. The immunotherapy of tumors has gradually become a new hotspot in the medical field in recent years. "Immunotherapy will set a new era of cancer treatment." This point can be found from the enthusiasm of the global pharmaceutical companies for the PD-1/PD-L1 target. Similarly, the speed of entry into China from BMS and Merck's PD-1 immunosuppressants can also tell the extent of market demand – every step of it has attracted market attention. However, not everyone can respond to PD-1/PD-L1, and gene sequencing has once again played an important role. In the early years, foreign products have not yet entered the product, and domestic products have not entered the late clinical stage. More sequencing companies are still based on targeted drug selection. According to incomplete statistics, there are only a few companies that have publicized immunotherapy in 2017. Among them, Yucei Bio and Rendong Medical have launched the Tumor Immune Cohort Study “Avalanche Plan†and “Ark Plan†respectively. As foreign products begin to enter the domestic market, domestic products enter the late stage of clinical or even the declaration stage, more and more enterprises are beginning to introduce immunotherapy accompanying diagnostic products. Even at CSCO in 2018, immunotherapy with diagnostics has become a fashion in the sequencing industry. Will these products have a wide range of homogenizations like prenatal testing and targeted testing? We are still unknown. But what is certain is that with the 2018 Nobel Prize in Medicine awarded to two cancer immunoscientists, James Allison and Tasuku Honio, research on tumor immunotherapy is bound to culminate. Swimming Crab Blue Swimming Crab,Hairy Crab,Lump Crab,Frozen Blue Swimming Crab ZHEJIANG EVERNEW SEAFOOD CO.,LTD , https://www.evernewseafood.com